Bull
$60.05
Scenario price
$51.570
+1.165 (+2.26%)At close
H.B. Fuller Company is a pureplay adhesives company. It operates as a formulator, manufacturer and marketer of adhesives, sealants and other specialty chemical products. Its Hygiene, Health and Consumable Adhesives segment manufactures and supplies adhesive products in the assembly, packaging, converting, nonwoven and hygiene, health and beauty, graphic arts and envelope markets. Its Engineering Adhesives segment produces and supplies industrial adhesives, such as reactive, light cure, two-part liquids, polyurethane, silicone, film and fast cure products. The Building Adhesive Solutions segment includes products used for the commercial roofing industry (pressure-sensitive adhesives, tapes and sealants) and heating, ventilation and air conditioning and insulation applications (duct sealants, weather barriers and fungicidal coatings and block fillers). It also includes caulks and sealants for the consumer market and professional trade, sold through retailers.
H.B. Fuller is not a strong buy at this moment, as the current price is $49.56, which is below the lowest analyst target of $62. The company has demonstrated a solid net income growth of 18% year-over-year to $79.2 million, but it missed revenue expectations by approximately $10 million, indicating potential challenges ahead. Additionally, the RSI is at 37.948, suggesting that the stock is nearing oversold territory but may not be ready for a rebound yet. The main risk is the declining sales volume, which could impact future earnings.
Deutsche Bank
$62
2026-09-29
Deutsche Bank
2026-09-29
Price Target
$62
JPMorgan
$66
2026-09-28
JPMorgan
2026-09-28
Price Target
$66
Citi
$63
2026-09-28
Citi
2026-09-28
Price Target
$63
Baird
$65
2026-09-25
Baird
2026-09-25
Price Target
$65
Deutsche Bank
$72
2026-06-30
Deutsche Bank
2026-06-30
Price Target
$72
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

H.B. Fuller Prices $850 Million Senior Unsecured Notes Offering

H.B. Fuller Declares Quarterly Cash Dividend

H.B. Fuller Appoints New Board Member

H.B. Fuller Reports Mixed Earnings Results

H.B. Fuller Q3 Earnings Report Analysis
H.B. Fuller Company is a pureplay adhesives company. It operates as a formulator, manufacturer and marketer of adhesives, sealants and other specialty chemical products. Its Hygiene, Health and Consumable Adhesives segment manufactures and supplies adhesive products in the assembly, packaging, converting, nonwoven and hygiene, health and beauty, graphic arts and envelope markets. Its Engineering Adhesives segment produces and supplies industrial adhesives, such as reactive, light cure, two-part liquids, polyurethane, silicone, film and fast cure products. The Building Adhesive Solutions segment includes products used for the commercial roofing industry (pressure-sensitive adhesives, tapes and sealants) and heating, ventilation and air conditioning and insulation applications (duct sealants, weather barriers and fungicidal coatings and block fillers). It also includes caulks and sealants for the consumer market and professional trade, sold through retailers. It operates in the Basic Materials sector (ADHESIVES & SEALANTS industry).
H.B. Fuller is not a strong buy at this moment, as the current price is $49.56, which is below the lowest analyst target of $62. The company has demonstrated a solid net income growth of 18% year-over-year to $79.2 million, but it missed revenue expectations by approximately $10 million, indicating potential challenges ahead. Additionally, the RSI is at 37.948, suggesting that the stock is nearing oversold territory but may not be ready for a rebound yet. The main risk is the declining sales volume, which could impact future earnings.
8 analysts cover FUL: 1 rate it Buy, 7 Hold and 0 Sell. The average price target is 70.00.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.